GSK toss­es a trio of clin­i­cal-stage drugs on tri­al fail­ures, win­now­ing out its res­pi­ra­to­ry pipeline as can­cer moves to cen­ter stage

Glax­o­SmithK­line is sweep­ing out three of its clin­i­cal stage pro­grams as it con­tin­ues to win­now out the weak from the strong in the pipeline. And there’s no sur­prise to see that res­pi­ra­to­ry is tak­ing the big hit here.

The phar­ma gi­ant’s Q3 roundup in­clud­ed taps for a trio of drugs fol­low­ing a re­assess­ment of their chances. Thrown in­to the scrap heap are:

• Danir­ix­in (GSK1325756), which didn’t get past a Phase IIb tri­al for COPD in Oc­to­ber. “This in­ter­im analy­sis showed danir­ix­in did not achieve the pri­ma­ry ef­fi­ca­cy end­point and this has changed the un­der­stand­ing of the risk/ben­e­fit pro­file of this as­set in COPD. Based on these da­ta GSK has tak­en the de­ci­sion to stop de­vel­op­ment in COPD.”
• TR­PV4 (GSK2798745) — called on fu­til­i­ty dur­ing a mid-stage study in chron­ic cough. They’ll keep an ear­ly-stage pro­gram for acute res­pi­ra­to­ry dis­tress syn­drom.
• TLR7 (GSK2245035). The drug flopped in a Phase II study for mild asth­ma, so out it goes. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER